The NCI preclinical screen of biological response modifiers.

James E Talmadge, I. J. Fidler, R. K. Oldham

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The development of successful approaches to immunotherapy is dependent upon proper consideration of the pathobiology of metastasis and the establishment of a better scientific understanding of the principles of biological response modification. The studies we have undertaken are aimed at the rational development of a preclinical data base to help provide this understanding. Ultimately, these studies will be correlated with clinical trials to assess the predictive value of the preclinical screen. We anticipate that the testing of biological response modifiers (BRMs) in a controlled but evolving system will help eliminate arbitrary decisions on the preparations and use of a given BRM and ultimately will contribute to the development of novel approaches for the treatment of disseminated cancer. Immunotherapy alone or in combination with other therapeutic modalities is an area of rapid evolution with tremendous potential as an adjuvant therapy of disseminated cancer.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalBehring Institute Mitteilungen
Issue number74
StatePublished - May 1 1984

Fingerprint

Immunologic Factors
Immunotherapy
Neoplasms
Testing
Therapeutics
Clinical Trials
Databases
Neoplasm Metastasis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The NCI preclinical screen of biological response modifiers. / Talmadge, James E; Fidler, I. J.; Oldham, R. K.

In: Behring Institute Mitteilungen, No. 74, 01.05.1984, p. 189-194.

Research output: Contribution to journalArticle

@article{66585f30874b434b96465f0acead4284,
title = "The NCI preclinical screen of biological response modifiers.",
abstract = "The development of successful approaches to immunotherapy is dependent upon proper consideration of the pathobiology of metastasis and the establishment of a better scientific understanding of the principles of biological response modification. The studies we have undertaken are aimed at the rational development of a preclinical data base to help provide this understanding. Ultimately, these studies will be correlated with clinical trials to assess the predictive value of the preclinical screen. We anticipate that the testing of biological response modifiers (BRMs) in a controlled but evolving system will help eliminate arbitrary decisions on the preparations and use of a given BRM and ultimately will contribute to the development of novel approaches for the treatment of disseminated cancer. Immunotherapy alone or in combination with other therapeutic modalities is an area of rapid evolution with tremendous potential as an adjuvant therapy of disseminated cancer.",
author = "Talmadge, {James E} and Fidler, {I. J.} and Oldham, {R. K.}",
year = "1984",
month = "5",
day = "1",
language = "English (US)",
pages = "189--194",
journal = "Behring Institute Mitteilungen",
issn = "0301-0457",
publisher = "Behringwerke AG",
number = "74",

}

TY - JOUR

T1 - The NCI preclinical screen of biological response modifiers.

AU - Talmadge, James E

AU - Fidler, I. J.

AU - Oldham, R. K.

PY - 1984/5/1

Y1 - 1984/5/1

N2 - The development of successful approaches to immunotherapy is dependent upon proper consideration of the pathobiology of metastasis and the establishment of a better scientific understanding of the principles of biological response modification. The studies we have undertaken are aimed at the rational development of a preclinical data base to help provide this understanding. Ultimately, these studies will be correlated with clinical trials to assess the predictive value of the preclinical screen. We anticipate that the testing of biological response modifiers (BRMs) in a controlled but evolving system will help eliminate arbitrary decisions on the preparations and use of a given BRM and ultimately will contribute to the development of novel approaches for the treatment of disseminated cancer. Immunotherapy alone or in combination with other therapeutic modalities is an area of rapid evolution with tremendous potential as an adjuvant therapy of disseminated cancer.

AB - The development of successful approaches to immunotherapy is dependent upon proper consideration of the pathobiology of metastasis and the establishment of a better scientific understanding of the principles of biological response modification. The studies we have undertaken are aimed at the rational development of a preclinical data base to help provide this understanding. Ultimately, these studies will be correlated with clinical trials to assess the predictive value of the preclinical screen. We anticipate that the testing of biological response modifiers (BRMs) in a controlled but evolving system will help eliminate arbitrary decisions on the preparations and use of a given BRM and ultimately will contribute to the development of novel approaches for the treatment of disseminated cancer. Immunotherapy alone or in combination with other therapeutic modalities is an area of rapid evolution with tremendous potential as an adjuvant therapy of disseminated cancer.

UR - http://www.scopus.com/inward/record.url?scp=0021424488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021424488&partnerID=8YFLogxK

M3 - Article

SP - 189

EP - 194

JO - Behring Institute Mitteilungen

JF - Behring Institute Mitteilungen

SN - 0301-0457

IS - 74

ER -